PF-Atlas › Clinical Trials › NCT04905693

Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease

Inhaled Treprostinil · Phase 3

Registry ID
NCT04905693
Phase
Phase 3
Status
Enrolling by invitation
Drug / intervention
Inhaled Treprostinil
Sponsor
United Therapeutics
Start
2022-09-06
Enrollment
1850
Locations
193

About this trial

Study RIN-PF-302 is designed to evaluate the long-term safety and tolerability of inhaled treprostinil in subjects with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis.

View NCT04905693 on ClinicalTrials.gov →

Explore related

Inhaled Treprostinil / Tyvaso — Treatment profileAll Inhaled Treprostinil trialsAll IPF trials

Related trials

Inhaled Treprostinil — TETON-1Inhaled Treprostinil — TETON-2Inhaled Treprostinil — NCT02630316
Medical disclaimer. This page summarizes public trial data for NCT04905693 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.